The inspiring story of Emma Betts premieres on Australian Story
16 April 2018
Emma Betts was only 22 years old when she learned that she had stage 4 melanoma. Emma shared her story with many by documenting her experience with melanoma on her blog Dear Melanoma. She sadly passed away at the age of 25 in April, 2017.
Australian Story's 'Dear Emma' is a tribute to the life and times of a young woman determined to raise awareness about melanoma. A true tear-jerker, the segment will explore how Emma and her husband Serge dealt with her heartbreak and how her parents Tamra and Leon, are continuing Emma’s legacy of encouraging others to contribute to life-saving research.
Although Emma was not a patient of Melanoma Institute Australia, she cared very deeply about people with melanoma and people at risk of melanoma around the country. She did everything she could to get the word out and raised a lot of funds for research at MIA - which reveals the complexity of the drivers of melanoma in younger people. It's not only about sun damage.
We're committed to weaving Emma's loving legacy into the work we'll be undertaking to draw attention to melanoma in young Australians and the research, treatment and education strategies we need to stop losing them to this disease.
Emma Betts started the national conversation about melanoma that Australia has to have. To continue Emma’s legacy, we need to keep that conversation going.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.